Sign up Australia
Proactive Investors - Run By Investors For Investors

ITL Health Group wins supply contract with New Zealand Blood Service

Two-year supply agreement, with possible ongoing renewals.
ITL Health Group wins supply contract with New Zealand Blood Service
The company’s half-yearly profit has doubled

ITL Health Group’s (ASX:ITD) ITL BioMedical division has signed a two year supply agreement for its SampLok Sampling Kit (SSK) with New Zealand Blood Service (NZBS).

SSK is an innovative product that is used in the blood banking market to transfer platelet samples during bacterial detection testing.

NZBS provides blood and tissue products and related services in New Zealand.

The NZBS contract builds on increased global SSK sales in 2016 when ITL signed many new contracts.

This includes a global distribution agreement with bioMérieux, a multinational biotechnology company.

ITL BioMedical provides specialty ancillary products for the blood culture testing market, estimated to be worth US$3.3 billion in 2016 and growing to US$4.8 billion by 2021.

In February 2017, ITL Health announced a profit after tax of $2.1 million for the 6 months to 31 December 2016, up 104% from the corresponding 2015 period.

The company reported a revenue of $17.5 million for the half year ending 31 December 2016, up 11% from the corresponding 2015 period.

ITL Health maintains four divisions including ITL BioMedical, ITL Healthcare, ITL Clinical and MyHealthTest.

The company holds a portfolio of 48 patents and sells into 55 countries.

ITL Health’s share price increased more than 60% since that start of 2017, last trading at $0.55.



Register here to be notified of future ITD Company articles

Related Articles

picture of pregnant woman
February 07 2017
MyLotus has been developed for women who have been trying to conceive for six months or more.
shutterstock_127456451.jpg
March 30 2017
PIFA Heparin PF/4 - a diagnostic test for allergic reactions to blood thinning agent Heparin - achieved an 85% jump in sales in 2016
1-Operation.jpg
January 19 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use